Third-generation smallpox vaccines: Challenges in the absence of clinical smallpox

Future Microbiology

Volumn 5, Issue 9, 2010, Pages 1367-1382

  Meseda, Clement A ^a   Weir, Jerry P ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

animal model; animal rule; immune response; orthopoxvirus; smallpox vaccine; vaccinia virus; variola virus

Indexed keywords

EM 63; GAMMA INTERFERON; LC16M8 VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; ECZEMA; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; ISCHEMIC HEART DISEASE; MYOPERICARDITIS; NONHUMAN; ORTHOPOXVIRUS; PERICARDITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; SMALLPOX; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; HUMANS; MICE; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; RABBITS; SMALLPOX; SMALLPOX VACCINE; VACCINATION; VACCINIA VIRUS; VARIOLA VIRUS;

ANIMALIA; ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 77957590341     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.98     Document Type: Review

References (148)

1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (Eds): Smallpox and its Eradication. World Health Organization Geneva, Switzerland (1988).
2. Davidovitch N, Greenberg Z: Public health, culture, and colonial medicine: smallpox and variolation in Palestine during the British Mandate. Public Health Rep. 122(3), 398-406 (2007).
3. Dinc G, Ulman YI: The introduction of variolation A La Turca to the West by Lady Mary Montagu and Turkeys contribution to this. Vaccine 25(21), 4261-4265 (2007).
4. Jannetta A: Jennerian vaccination and the creation of a national public health agenda in Japan, 1850-1900. Bull. Hist. Med. 83(1), 125-140 (2009).
5. Mark C, Rigau-Perez JG: The worlds first immunization campaign: the Spanish Smallpox Vaccine Expedition, 1803-1813. Bull. Hist. Med. 83(1), 63-94 (2009).
6. Breman JG, Henderson DA: Diagnosis and management of smallpox. N. Engl. J. Med. 346(17), 1300-1308 (2002).
7. CDC: Public Health Service recommendations on smallpox vaccination. Morb. Mortal. Wkl. Rep. 20, 339 (1971).
8. Ladnyi ID, Breman JG: Smallpox eradication: progress and problems. Dev. Biol. Stand. 41, 281-290 (1978).
9. Institute of Medicine: Live Variola Virus: Considerations for Continuing Research. The National Academies Press, Washington, DC, USA (2009).
10. Moussatche N, Damaso CR, McFadden: When good vaccines go wild: feral orthopoxvirus in developing countries and beyond. J. Infect. Dev. Ctries 2(3), 156-173 (2008).
11. Levine RS, Peterson AT, Yorita KL, Carroll D, Damon IK, Reynolds MG: Ecological niche and geographic distribution of human monkeypox in Africa. PLoS One 2(1), e176 (2007).
12. Meyer H, Perrichot M, Stemmler M et al.: Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J. Clin. Microbiol. 40(8), 2919-2921 (2002).
13. Heymann DL, Szczeniowski M, Esteves K: Re-emergence of monkeypox in Africa: a review of the past six years. Br. Med. Bull. 54(3), 693-702 (1998).
14. CDC: Human monkeypox - Kasai Oriental, Zaire, 1996-1997. Morb. Mortal. Wkl. Rep. 46(14), 304-307 (1997)
15. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I: Human monkeypox, 1970-1979. Bull. World Health Organ. 58(2), 165-182 (1980).
16. Trindade GS, Lobato ZI, Drumond BP et al.: Short report: isolation of two vaccinia virus strains from a single bovine vaccinia outbreak in rural area from Brazil: implications on the emergence of zoonotic orthopoxviruses. Am. J. Trop. Med. Hyg. 75(3), 486-490 (2006).
17. Silva-Fernandes AT, Travassos CE, Ferreira JM et al.: Natural human infections with vaccinia virus during bovine vaccinia outbreaks. J. Clin. Virol. 44(4), 308-313 (2009).
18. Yadav S, Hosamani M, Balamurugan V, Bhanuprakash V, Singh RK: Partial genetic characterization of viruses isolated from pox-like infection in cattle and buffaloes: evidence of buffalo pox virus circulation in Indian cows. Arch. Virol. 155(2), 255-261 (2010).
19. Nitsche A, Pauli G: Sporadic human cases of cowpox in Germany. Euro. Surveill. 12(4), e070419 3 (2007).
20. Pelkonen PM, Tarvainen K, Hynninen A et al.: Cowpox with severe generalized eruption, Finland. Emerg. Infect. Dis. 9(11), 1458-1461 (2003).
21. Vorou RM, Papavassiliou VG, Pierroutsakos IN: Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 21(2), 153-156 (2008).
22. Reed KD, Melski JW, Graham MB et al.: The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350(4), 342-350 (2004).
23. CDC: Multistate outbreak of monkeypox - Illinois, Indiana, and Wisconsin. Morb. Mortal. Wkl. Rep. 52(23), 537-540 (2003)
24. Lane JM, Ruben FL, Neff JM, Millar JD: Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122(4), 303-309 (1970).
25. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316(11), 673-676 (1987).
26. Kempe CH, Fulginiti V, Minamitani M, Shinefield H: Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78). Pediatrics 42(6), 980-985 (1968).
27. Vora S, Damon I, Fulginiti V et al.: Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46(10), 1555-1561 (2008).
28. Arness MK, Eckart RE, Love SS et al.: Myopericarditis following smallpox vaccination. Am. J. Epidemiol. 160(7), 642-651 (2004).
29. Mora LF, Khan AH, Sperling LS: Cardiac complications after smallpox vaccination. South Med. J. (2009) (Epub ahead of print).
30. Van Dam CN, Syed S, Eron JJ et al.: Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin. Clin. Infect. Dis. 48(4), E47-E49 (2009).
31. Bryant-Genevier M, OConnell K, Ball R, Braun MM, McMahon A: Passive surveillance for generalized vaccinia in the United States using the Vaccine Adverse Event Reporting System (VAERS). Vaccine 24(17), 3632-3635 (2006).
32. Halsell JS, Riddle JR, Atwood JE et al.: Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289(24), 3283-3289 (2003).
33. Eckart RE, Shry EA, Jones SO IV, Atwood JE, Grabenstein JD: Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients
34. Jacobson IG, Smith TC, Smith B, Wells TS, Reed RJ, Ryan MA: US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination. Vaccine 26(32), 4048-4056 (2008).
35. Rivers TM: Cultivation of vaccine virus for Jennerian prophylaxis in man. J. Exp. Med. 54(4), 453-461 (1931).
36. Mayr A, Stickl H, Muller HK, Danner K, Singer H: The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism [authors translation]. Zentralbl. Bakteriol. B 167(5-6), 375-390 (1978).
37. Hashizume S, Yoshizawa H, Morita M, Suzuki K: Properties of attenuated mutant of vaccinia virus LC16m8, derived from Lister strain. In: Vaccinia Viruses as Vectors for Vaccine Antigens. Quinnan (Ed.), Elsevier Science Publishing Co., NY, USA 87-99 (1985).
38. Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA: The immunology of smallpox vaccines. Curr. Opin. Immunol. 21(3), 314-320 (2009).
39. Paran N, Sutter G: Smallpox vaccines: new formulations and revised strategies for vaccination. Hum. Vaccin. 5(12), 824-831 (2009).
40. Jacobs BL, Langland JO, Kibler KV et al.: Vaccinia virus vaccines: past present and future. Antiviral Res. 84(1), 1-13 (2009).
41. Weltzin R, Liu J, Pugachev KV et al.: Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9(9), 1125-1130 (2003).
42. Greenberg RN, Kennedy JS: ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Invest. Drugs 17(4), 555-564 (2008).
43. Monath TP, Caldwell JR, Mundt W et al.: ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. Suppl. 2, S31-S44 (2004).
44. Weber HG: Utilization of the MVA-immunization schedule from the view point of the public health service. Fortschr. Med. 95(21), 1381-1386 (1977).
45. Cosma A, Nagaraj R, Staib C et al.: Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res. Hum. Retroviruses 23(6), 782-793 (2007).
46. Kretzschmar M, Wallinga J, Teunis P, Xing S, Mikolajczyk R: Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med. 3(8), E272 (2006).
47. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M: LC16m8: an attenuated smallpox vaccine. Vaccine 24(47-48), 7009-7022 (2006).
48. Tartaglia J, Perkus ME, Taylor J et al.: NYVAC: a highly attenuated strain of vaccinia virus. Virology 188(1), 217-232 (1992).
49. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG: The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341(1), 91-101 (2005)
50. Jentarra GM, Heck MC, Youn JW et al.: Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine 26(23), 2860-2872 (2008).
51. Earl PL, Americo JL, Wyatt LS et al.: Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428(6979), 182-185 (2004)
52. Meseda CA, Garcia AD, Kumar A et al.: Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339(2), 164-175 (2005).
53. Earl PL, Americo JL, Wyatt LS et al.: Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl Acad. Sci. USA 105(31), 10889-10894 (2008).
54. Midgley CM, Putz MM, Weber JN, Smith GL: Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J. Gen. Virol. 89(Pt 12), 2992-2997 (2008).
55. He Y, Manischewitz J, Meseda CA et al.: Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine - induced immunity. J. Infect. Dis.196(7), 1026-1032 (2007).
56. Fogg CN, Americo JL, Earl PL et al.: Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J. Virol. 82(16), 8022-8029 (2008).
57. Saito T, Fujii T, Kanatani Y et al.: Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 301(10), 1025-1033 (2009).
58. Wilck MB, Seaman MS, Baden LR et al.: Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J. Infect. Dis. 201(9), 1361-1370 (2010).
59. Seaman MS, Wilck MB, Baden LR et al.: Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J. Infect. Dis. 201(9), 1353-1360 (2010).
60. Tine JA, Lanar DE, Smith DM et al.: NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64(9), 3833-3844 (1996).
61. Esteban M: Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum. Vaccin. 5(12), 867-871 (2009).
62. Weyer J, Rupprecht CE, Nel LH: Poxvirus-vectored vaccines for rabies - a review. Vaccine 27(51), 7198-7201 (2009).
63. Meseda CA, Mayer AE, Kumar A et al.: Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin. Vaccine Immunol. 16(9), 1261-1271 (2009).
64. Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S: A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J. Virol. 84(8), 3909-3920 (2010).
65. Garza NL, Hatkin JM, Livingston V et al.: Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 27(40), 5496-5504 (2009).
66. Stittelaar KJ, van Amerongen G, Kondova I et al.: Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79(12), 7845-7851 (2005).
67. Saijo M, Ami Y, Suzaki Y et al.: LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J. Virol. 80(11), 5179-5188 (2006).
68. Empig C, Kenner JR, Perret-Gentil M et al.: Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 24(17), 3686-3694 (2006).
69. Hammarlund E, Lewis MW, Hansen SG et al.: Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9(9), 1131-1137 (2003).
70. Lai CF, Gong SC, Esteban M: The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J. Virol. 65(10), 5631-5635 (1991).
71. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L: Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254(1), 71-80 (1999).
72. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B: Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78(19), 10230-10237 (2004).
73. Davies DH, McCausland MM, Valdez C et al.: Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79(18), 11724-11733 (2005).
74. Sakhatskyy P, Wang S, Chou TH, Lu S: Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355(2), 164-174 (2006).
75. Benhnia MR, McCausland MM, Su HP et al.: Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J. Virol. 82(7), 3751-3768 (2008).
76. Nelson GE, Sisler JR, Chandran D, Moss B: Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 380(2), 394-401 (2008).
77. Sirven P, Castelli FA, Probst A, Szely N, Maillere B: In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R. Mol. Immunol. 46(7), 1481-1487 (2009).
78. Smith GL, Vanderplasschen A, Law M: The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83(Pt 12), 2915-2931 (2002).
79. Roberts KL, Smith GL: Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 16(10), 472-479 (2008).
80. Condit RC, Moussatche N, Traktman P: In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 66, 31-124 (2006).
81. Appleyard G, Hapel AJ, Boulter EA: An antigenic difference between intracellular and extracellular rabbitpox virus. J. Gen. Virol. 13(1), 9-17 (1971).
82. Boulter EA, Zwartouw HT, Titmuss DH, Maber HB: The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am. J. Epidemiol. 94(6), 612-620 (1971).
83. Sette A, Grey H, Oseroff C et al.: Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 27(Suppl. 6), G21-G26 (2009).
84. Moutaftsi M, Tscharke DC, Vaughan K et al.: Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol. 5(2), 221-239 (2010).
85. McIntosh K, Cherry JD, Benenson AS et al.: Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Standard percutaneous revaccination of children who receive primary percutaneous vaccination. J. Infect. Dis. 135(1), 155-166 (1977).
86. Mack TM, Noble J Jr, Thomas DB: A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21(2), 214-218 (1972).
87. Fenner F: Studies in infectious ectromelia of mice; immunization of mice against ectromelia with living vaccinia virus. Aust. J. Exp. Biol. Med. Sci. 25(Pt 3), 257-274 (1947).
88. Kempe CH, Bowles C, Meiklejohn G et al.: The use of vaccinia hyperimmune g-globulin in the prophylaxis of smallpox. Bull. World Health Organ. 25, 41-48 (1961).
89. Goldstein JA, Neff JM, Lane JM, Koplan JP: Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 55(3), 342-347 (1975).
90. Lustig S, Maik-Rachline G, Paran N et al.: Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 27(11), 1691-1699 (2009).
91. Edghill-Smith Y, Golding H, Manischewitz J et al.: Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11(7), 740-747 (2005).
92. Chaudhri G, Panchanathan V, Bluethmann H, Karupiah G: Obligatory requirement for antibody in recovery from a primary poxvirus infection. J. Virol. 80(13), 6339-6344 (2006).
93. Panchanathan V, Chaudhri G, Karupiah G: Antiviral protection following immunization correlates with humoral but not cell-mediated immunity. Immunol. Cell Biol. 88(4), 461-467 (2010).
94. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD: Inhibition of viral replication by interferon-g-induced nitric oxide synthase. Science 261(5127), 1445-1448 (1993).
95. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J: Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J. Virol. 70(12), 8301-8309 (1996).
96. Chaudhri G, Panchanathan V, Buller RM et al.: Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc. Natl Acad. Sci. USA 101(24), 9057-9062 (2004).
97. Panchanathan V, Chaudhri G, Karupiah G: Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80(13), 6333-6338 (2006).
98. Senkevich TG, Ward BM, Moss B: Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J. Virol. 78(5), 2357-2366 (2004).
99. Senkevich TG, Ojeda S, Townsley A, Nelson GE, Moss B: Poxvirus multiprotein entry-fusion complex. Proc. Natl Acad. Sci. USA 102(51), 18572-18577 (2005).
100. Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ: Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345(1), 231-243 (2006)
101. Hooper JW, Thompson E, Wilhelmsen C et al.: Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78(9), 4433-4443 (2004).
102. Golden JW, Hooper JW: Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology 377(1), 19-29 (2008).
103. Aldaz-Carroll L, Whitbeck JC, Ponce de Leon M et al.: Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J. Virol. 79(10), 6260-6271 (2005).
104. Barefoot B, Thornburg NJ, Barouch DH et al.: Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26(48), 6108-6118 (2008).
105. Hooper JW, Ferro AM, Golden JW et al.: Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28(2), 494-511 (2009).
106. OConnell CJ, Karzon DT, Barron AL, Plaut ME, Ali VM: Progressive vaccinia with normal antibodies. A case possibly due to deficient cellular immunity. Ann. Intern. Med. 60, 282-289 (1964).
107. Blanden RV: Mechanisms of recovery from a generalized viral infection: mousepox. II. Passive transfer of recovery mechanisms with immune lymphoid cells. J. Exp. Med. 133(5), 1074-1089 (1971).
108. Mullbacher A, Lobigs M, Yewdell JW, Bennink JR, Tha Hla R, Blanden RV: High peptide affinity for MHC class I does not correlate with immunodominance. Scand. J. Immunol. 50(4), 420-426 (1999)
109. Ennis FA, Cruz J, Demkowicz WE Jr, Rothman AL, McClain DJ: Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-g-producing T cells after smallpox vaccination. J. Infect. Dis. 185(11), 1657-1659 (2002).
110. Kim SH, Yeo SG, Cho JH et al.: Cell-mediated immune responses to smallpox vaccination. Clin. Vaccine Immunol. 13(10), 1172-1174 (2006).
111. Dong Y, Denny TN: HLA-A2-restricted human CD8+ cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses. J. Infect. Dis. 194(2), 168-175 (2006).
112. Terajima M, Cruz J, Raines G et al.: Quantitation of CD8+ T cell responses to newly identified HLA-A0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J. Exp. Med. 197(7), 927-932 (2003).
113. Flesch IE, Woo WP, Wang Y et al.: Altered CD8+ T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice. J. Immunol. 184(1), 45-55 (2010).
114. Tscharke DC, Karupiah G, Zhou J et al.: Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201(1), 95-104 (2005).
115. Doherty PC, Biddison WE, Bennink JR, Knowles BB: Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype. J. Exp. Med. 148(2), 534-543 (1978).
116. Phelps A, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO: Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model. Vaccine 23(27), 3500-3507 (2005).
117. Kaufman DR, Goudsmit J, Holterman L et al.: Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J. Virol. 82(14), 6829-6837 (2008).
118. Yu W, Fang Q, Zhu W et al.: One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. Vaccine 28(9), 2088-2096 (2010).
119. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr: Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. J. Infect. Dis. 194(4), 435-443 (2006).
120. Frey SE, Newman FK, Kennedy JS et al.: Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 27(10), 1637-1644 (2009).
121. Luttge BG, Moyer RW: Suppressors of a host range mutation in the rabbitpox virus serpin SPI-1 map to proteins essential for viral DNA replication. J. Virol. 79(14), 9168-9179 (2005).
122. Roper RL, Wolffe EJ, Weisberg A, Moss B: The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J. Virol. 72(5), 4192-4204 (1998). (Pubitemid 28188724)
123. Hooper JW, Golden JW, Ferro AM, King AD: Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25(10), 1814-1823 ( 2007).
124. Heraud JM, Edghill-Smith Y, Ayala V et al.: Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177(4), 2552-2564 (2006).
125. Putz MM, Midgley CM, Law M, Smith GL: Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med. 12(11), 1310-1315 (2006).
126. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL: DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266(2), 329-339 (2000).
127. Hooper JW, Custer DM, Thompson E: Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306(1), 181-195 (2003).
128. Trojan A, Rajeswaran R, Montemurro M, Mutsch M, Steffen R. Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination. J. Clin. Virol. 40(1), 80-83 (2007).
129. Davies DH, Wyatt LS, Newman FK et al.: Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J. Virol. 82(2), 652-663 (2008).
130. Bedson HS, Duckworth MJ: Rabbit pox: an experimental study of the pathways of infection in rabbits. J. Pathol. Bacteriol. 85, 1-20 (1963).
131. Westwood JC, Boulter EA, Bowen ET, Maber HB: Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br. J. Exp. Pathol. 47(5), 453-465 (1966).
132. Adams MM, Rice AD, Moyer RW: Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J. Virol. 81(20), 11084-11095 (2007).
133. Esteban DJ, Buller RM: Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 86(Pt 10), 2645-2659 (2005).
134. Xiao Y, Aldaz-Carroll L, Ortiz AM et al.: A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25(7), 1214-1224 (2007).
135. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L: The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81(12), 1581-1600 (2001).
136. MacNeill AL, Moldawer LL, Moyer RW: The role of the cowpox virus crmA gene during intratracheal and intradermal infection of C57BL/6 mice. Virology 384(1), 151-160 (2009).
137. Schultz DA, Sagartz JE, Huso DL, Buller RM: Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology 383(1), 86-92 (2009).
138. Tesh RB, Watts DM, Sbrana E, Siirin M, Popov VL, Xiao SY: Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus. Emerg. Infect. Dis. 10(9), 1563-1567 (2004).
139. Xiao SY, Sbrana E, Watts DM, Siirin M, da Rosa AP, Tesh RB: Experimental infection of prairie dogs with monkeypox virus. Emerg. Infect. Dis. 11(4), 539-545 (2005).
140. Hutson CL, Olson VA, Carroll DS et al.: A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J. Gen. Virol. 90(Pt 2), 323-333 (2009).
141. Jahrling PB, Hensley LE, Martinez MJ et al.: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl Acad. Sci. USA 101(42), 15196-15200 (2004).
142. Eckart RE, Shry EA, Atwood JE et al.: Smallpox vaccination and ischemic coronary events in healthy adults. Vaccine 25(50), 8359-8364 (2007)
143. US FDA, HHS: New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final Rule. Fed. Regist. 67, 37988-37998 (2002).
144. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP: Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J. Immunol. 183(5), 3150-3159 (2009).
145. Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN: Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325(2), 425-431 (2004).
146. Aldaz-Carroll L, Xiao Y, Whitbeck JC et al.: Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J. Virol. 81(15), 8131-8139 (2007).
147. Walsh SR, Gillis J, Peters B et al.: Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques. Vaccine 27(36), 4990-5000 (2009).
148. Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, Sutter G: Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J. Virol. 83(6), 2540-2552 (2009).